Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Here’s IDIX’s EASL press release describing the one oral presentation
and three poster presentations to be made at the conference in late April.
The oral presentation is on the antiviral efficacy of IDX184 in chimps, and
it describes how efficacy is correlated to the plasma levels of the active
triphosphate metabolite. A poster presentation on IDX184 gives PK data
and qualitative safety info from the phase-1/2 trial in progress (see abstract
in #msg-36392616); together, these two IDX184 studies make a strong case
for the underlying rationale of IDX184 as a nucleotide prodrug. The two
other poster presentations contain preclinical data on the IDX136/316
protease inhibitors and IDX375, the non-nuke polymerase inhibitor. IDIX
is the only company with HCV drug candidates in all three categories:
nuke, non-nuke, and PI.

http://finance.yahoo.com/news/Idenix-Announces-Data-prnews-14681434.html

›Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver

Wednesday March 18, 2009, 4:05 pm EDT

CAMBRIDGE, Mass., March 18 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that four abstracts from the company's hepatitis C antiviral discovery and development programs have been accepted for presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL, April 22-26, 2009 in Copenhagen, Denmark). Full abstracts can now be viewed at the EASL website at www.easl.ch.

The four accepted abstracts are as follows:

* ANTIVIRAL ACTIVITY OF THE LIVER-TARGETED NUCLEOTIDE HCV POLYMERASE INHIBITOR IDX184 CORRELATES WITH TROUGH SERUM LEVELS OF THE NUCLEOSIDE METABOLITE IN HCV-INFECTED CHIMPANZEES - Abstract #583; Oral presentation; Parallel session entitled: Hepatitis C Virus Drug Development II; Session date: Friday, April 24, 2009; Session time: 16:00 - 18:00

* IDX184, A LIVER-TARGETED NUCLEOTIDE HCV POLYMERASE INHIBITOR: RESULTS OF A FIRST-IN-MAN SAFETY AND PHARMACOKINETIC STUDY - Abstract #1375 [see #msg-36392616]; Poster presentation; Saturday, April 25, 2009

* PRECLINICAL PROFILES OF IDX136 AND IDX316, TWO NOVEL MACROCYCLIC HCV PROTEASE INHIBITORS - Abstract #1449; Poster presentation; Thursday, April 23, 2009

* PRECLINICAL PHARMACOKINETIC AND SAFETY PROFILE OF IDX375, A NOVEL AND POTENT NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR - Abstract #1442; Poster presentation; Thursday, April 23, 2009

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.‹